Necmi Eren

Prof. Dr. Necmi Eren


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2018 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
NENecmi Eren
Necmi Eren
OGOzkan Gungor
Ozkan Gungor
IKIsmail Kocyigit
Ismail Kocyigit
FGFatma Betul Guzel
Fatma Betul Guzel
EEErtugrul Erken
Ertugrul Erken
ATAydin Turkmen
Aydin Turkmen

4 June 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
SOSavas Ozturk
Savas Ozturk
KTKenan Turgutalp
Kenan Turgutalp
MAMustafa Arici
Mustafa Arici
MGMahmut Gok
Mahmut Gok
MImahmud islam
mahmud islam
KAKenan Ates
Kenan Ates
Objective Older adults with comorbidities have been reported to be at higher risk for adverse outcomes of Coronavirus disease 2019(COVID-19). The characteristics of COVID-19 in older patients and its clinical outcomes in different kidney disease groups are not well known. Methods Data were retrieved from a national multicentric database supported by Turkish Society of Nephrology, which consists of retrospectively collected data between April 17, 2020, and December 31, 2020. Hospitalized patients aged 18 years or older with confirmed COVID-19 diagnosis suffering from stage 3-5 chronic kidney disease(CKD) or on maintenance hemodialysis(HD) treatment were included in the database. Non-uremic hospitalized patients with COVID-19 were also included as the control group. Results We included 879 patients [388(44.1%) female, median age: 63(IQR:50-73) years]. The percentage of older patients in the CKD group was 68.8%(n=188/273), in HD group was 49.0%(n=150/306) and in the control group was 30.4%(n=70/300). Comorbidities were higher in the CKD and HD groups. The rate of presentation with severe-critical disease was higher in the older CKD and HD groups (43.6%, 55.3%, 16.1%, respectively). Among older patients, the intensive care unit(ICU) admission rate was significantly higher in the CKD and HD group than in the control group (38.8%, 37.3%, and 15.7%, respectively). In-hospital mortality or death and/or ICU admission rates in the older group were significantly higher in the CKD (29.3% and 39.4%) and HD group (26.7% and 30.1%) compared to the control group (8.6% and 17.1%). In the multivariate analysis, in-hospital mortality rates in CKD and HD groups were higher than control group [Hazard ratio(HR): 4.33([95% confidence interval(CI): 1.53-12.26] and HR: 3.09(95%CI: 1.04-9.17), respectively]. Conclusion Among older COVID-19 patients, in-hospital mortality is significantly higher in those with stage 3-5 CKD and on maintenance HD than older patients without CKD regardless of demographic characteristics, comorbidities, clinical and laboratory data on admission.

1 August 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
SBSibel BEK
Sibel BEK
BÜBerna Üstüner
Berna Üstüner
NENecmi Eren
Necmi Eren
ZSZeynep Sentürk
Zeynep Sentürk
BGBetül Kalender Gönüllü
Betül Kalender Gönüllü
SUMMARY BACKGROUND Hepcidin is an important regulator of iron homeostasis. OBJECTIVES This cross-sectional study was conducted to evaluate the association between hepcidin and components of metabolic syndrome in patients with chronic kidney disease (CKD). DESIGN AND SETTING 103 CKD patients and 59 healthy volunteers were included in the study from the University Hospital. METHODS Serum hepcidin levels were measured by enyzme-linked immunosorbent assay (ELISA) test. As for the study parameters, age, sex, body mass index, renal diseases, serum biochemistry, complete blood count, iron and total iron-binding capacity, ferritin, high-sensitive C-reactive protein (hsCRP), C- reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. RESULTS The mean age of the patients was 58.63 ± 11.8 years. Hepcidin level was significantly associated with hypertension and higher uric acid levels (P < 0.05). There was a positive correlation between hepcidin and urea, uric acid, creatinine, ferritin, CRP, ESR, phosphorus, triglyceride, low-density lipoprotein (LDL), proteinuria and albuminuria in 24-hour urine collection. A negative correlation was found between hepcidin and estimated glomerular filtration rate (eGFR), hemoglobin, hematocrit, calcium, 25 OH vitamin D, pH, and bicarbonate levels. CONCLUSION Hepcidin, a well-known hormone regulator of iron metabolism, may play an important role in the pathogenesis of metabolic syndrome in patients with CKD, and further studies might delineate in-depth its potential as a promising early marker in these patients.

27 October 2020 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
NENecmi Eren
Necmi Eren
OGOzkan Gungor
Ozkan Gungor
FSFeyza Nur Sarisik
Feyza Nur Sarisik
FSFatih Sokmen
Fatih Sokmen
DTDidem Tutuncu
Didem Tutuncu
ACAyse Cefle
Ayse Cefle
Objective: Renal tubular acidosis (RTA) is a clinical manifestation that occurs with insufficiency in restoring bicarbonate or disruption in hydrogen ion elimination as a result of a disruption in tubulus functions, causing normal anion gap-opening metabolic acidosis. In the present study, we aimed to investigate the prevalence of RTA in the largest systemic lupus erythematosus (SLE) patient population to date. Materials and Methods: SLE patients, who were followed up in 2 different healthcare centers, were included. Patients with metabolic acidosis (pH <7.35 and HCO3 <22 mEq/L) in venous blood gas analysis were determined. The serum and urine anion GAP of these patients were estimated, and the urine pH was assessed. RTA presence was evaluated as metabolic acidosis with a normal serum anion gap and a positive urine anion GAP. Results: A total of 108 patients were included in the present study. The mean age of the patients was 41.5 ± 1.2 and 87% were female. The SLE diagnosis duration was 75 ± 5 months. The mean creatinine value ​​was 0.6 ± 0.1 mg/dL and the mean eGFR was 111 ± 2 mL/min. According to the blood gas analysis, 18 patients (16.7% of the total) had RTA. Sixteen of these patients had type 1 RTA and 2 had type 2 RTA; type 4 RTA was not determined in any of the patients. Conclusion: RTA should be considered in SLE patients even if they have normal eGFR values. This is the largest study to examine the prevalence of RTA in SLE patients in the literature.

15 April 2025 in Turkish Journal of Nephrology
Verified
Journal Article
Open access
NSNurhan Seyahi
Nurhan Seyahi
IKIsmail Kocyigit
Ismail Kocyigit
NENecmi Eren
Necmi Eren
HTHalil Zeki Tonbul
Halil Zeki Tonbul
ETErhan Tatar
Erhan Tatar
KAKenan Ateş
Kenan Ateş
Background: Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis (PD), and transplan tation annually. Registry reports are printed every year as a booklet, and this is the 34th year of the registry reports. The registry is in close collaboration with international registries. Methods: In this paper, we summarized data from the 2023 registry report and provided yearly trends for managing end stage kidney disease. Results: The number of patients on kidney replacement therapy (KRT) increased; at the end of 2023, 89 527 patients were on KRT. The prevalence and incidence of end-stage kidney disease were 1048.7 and 159.8 per million population, respec tively. Diabetes was the most common cause of end-stage kidney disease. Hemodialysis (70.88%) was the most common type of treatment modality, followed by transplantation (25.01%) and PD (4.11%). Conclusion: End-stage kidney disease is a critical and growing health problem for our country. The kidney registry of the Turkish Society of Nephrology is one of the leading tools for providing current and sound data on this public health problem. Cite this article as: Seyahi N, Koçyi#it ", Eren N, et!al. Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2025;34(2):141-148.

2 August 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SUSami Uzun
Sami Uzun
EOEbru Gok Oguz
Ebru Gok Oguz
AYAbdülmecit Yıldız
Abdülmecit Yıldız
UDULVER DERICI
ULVER DERICI
ECEmre Cankaya
Emre Cankaya
SOSavas Ozturk
Savas Ozturk
ANCA-associated glomerulonephritis (ANCA-GN) is a leading cause of pauci-immune crescentic GN. Recent evidence indicates that complement activation, marked by C3 deposition in glomeruli, may contribute to more severe renal injury and influence renal outcomes. We aim to evaluate the clinical, histopathological, and prognostic implications of C3 deposition in ANCA-GN. We retrospectively analyzed 195 patients with biopsy-proven ANCA-GN from the Turkish Society of Nephrology Glomerular Diseases registry from 2002 to 2022. Patients were classified as C3-positive or C3-negative according to kidney biopsy immunofluorescence findings. Clinical characteristics, histopathologic lesion profiles, and follow-up outcomes (remission, relapse, and survival) were compared between the two groups. Of 195 patients, 54 (27.7%) had C3 deposition. The C3-negative group was more likely to exhibit PR3-ANCA positivity, whereas the C3-positive group was strongly associated with the presence of MPO-ANCAs (22.2% vs. 77.8%; p = 0.001). Compared with C3-negative patients, C3-positive patients had higher levels of proteinuria (2026 mg/day vs. 1790 mg/day; p = 0.049) and lower HDL levels (30 mg/dL vs. 37 mg/dL; p = 0.009). Fibrocellular crescents were more common in C3-positive patients than in C3-negative patients (p < 0.001). Immune complex deposits, including IgG (26.4% vs. 3.5%; p < 0.001), IgA (14.8% vs. 0.7%; p < 0.001), IgM (25.0% vs. 3.5%; p < 0.001), and C1q (13.7% vs. 0.8%; p < 0.001) were significantly greater in the C3-positive group. However, no significant difference was detected in overall survival (85.8% for C3-negative patients vs. 88.9% for C3-positive patients; p = 0.249). Similarly, the remission (62.1% vs. 59.4%; p = 0.786) and relapse rates (14.8% vs. 11.1%; p = 0.532) did not differ between the groups. In ANCA-GN, glomerular C3 deposition is associated with an MPO-ANCA serotype, greater proteinuria, and more severe renal histology (including immune-complex deposition and more fibrocellular crescents), indicating more pronounced complement activation and tissue injury. However, C3 deposition did not predict worse patient or renal survival in our cohort. Not applicable.